Caribou Biosciences Inc (CRBU) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.30 (-0.76%), Market cap $0.21B, 52-week low–high $0.94 ~ $2.84.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was inc
Financial statements, price targets, institutional (13F) holdings and related news for Caribou Biosciences Inc are updated in real time on BlackAll Trade.
Caribou Biosciences Inc trades at $1.30 (-0.76%). Real-time quotes and charts are available on BlackAll Trade.
Caribou Biosciences Inc has a market cap of about $0.21B.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform